Trial Profile

An Open Clinical Trial to Evaluate GanovoDanoprevir Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 31 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Danoprevir (Primary) ; Ritonavir (Primary) ; Interferon alpha
Indications COVID-19 pneumonia; SARS-CoV-2 acute respiratory disease
Focus Adverse reactions

Most Recent Events

25 Nov 2020 Results evaluating the safety and efficacy of of danoprevir boosted by ritonavir on treatment naive and experienced COVID-19 patients, published in the Medicine
24 Mar 2020 According to an Ascletis media release, data from this small-sample clinical study was published in medRxiv.
24 Mar 2020 Results presented in an Ascletis media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com